Coherus Oncology (CHRS) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Coherus Oncology is set to release its Q2 2025 earnings on August 7th, with analysts predicting an earnings per share of ($0.25) for the quarter.
• Shares of CHRS stock have recently fallen by 6.6% and are currently trading at $0.88, with a market cap of $101.76 million.
• Analysts have varied ratings for Coherus, with HC Wainwright setting a $7.00 price target, while UBS Group lowered its target to $1.05 and Wall Street Zen downgraded it to a "sell" rating.

Coherus Oncology (NASDAQ:CHRS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $9.28 million for the quarter.

Coherus Oncology (NASDAQ:CHRS - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). The business had revenue of $7.60 million for the quarter, compared to analysts' expectations of $59.79 million. During the same quarter in the previous year, the business earned ($0.32) earnings per share. On average, analysts expect Coherus Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus Oncology Trading Up 8.1%

Shares of CHRS stock traded up $0.07 during trading hours on Tuesday, hitting $0.94. 642,585 shares of the company's stock were exchanged, compared to its average volume of 1,699,275. Coherus Oncology has a 12-month low of $0.66 and a 12-month high of $2.43. The business's 50 day simple moving average is $0.84 and its 200-day simple moving average is $0.95. The company has a market capitalization of $108.75 million, a PE ratio of -0.83 and a beta of 0.89.

Analyst Upgrades and Downgrades

CHRS has been the topic of several analyst reports. Wall Street Zen downgraded shares of Coherus Oncology from a "hold" rating to a "sell" rating in a research note on Tuesday, May 20th. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Coherus Oncology in a research note on Tuesday, April 29th. Finally, UBS Group reiterated a "neutral" rating and issued a $1.05 price target (down previously from $1.50) on shares of Coherus Oncology in a report on Thursday, April 24th.

Insiders Place Their Bets

In other news, Director Mats Wahlstrom sold 99,988 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $0.74, for a total transaction of $73,991.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 8.08% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Coherus Oncology

An institutional investor recently raised its position in Coherus Oncology stock. Acadian Asset Management LLC lifted its stake in Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) by 52,980.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 196,927 shares of the biotechnology company's stock after purchasing an additional 196,556 shares during the quarter. Acadian Asset Management LLC owned 0.17% of Coherus Oncology worth $158,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 72.82% of the company's stock.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.